Patents by Inventor Thomas Schupp

Thomas Schupp has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6858404
    Abstract: Nucleic acid molecules are isolated from Sorangium cellulosum that encode polypeptides necessary for the biosynthesis of epothilone. Disclosed are methods for the production of epothilone in recombinant hosts transformed with the genes of the invention. In this manner, epothilone can be produced in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer.
    Type: Grant
    Filed: November 13, 2001
    Date of Patent: February 22, 2005
    Assignee: Novartis AG
    Inventors: Thomas Schupp, James Madison Ligon, Istvan Molnar, Ross Zirkle, Devon Dawn Cyr, Jörn Görlach
  • Publication number: 20040142990
    Abstract: The invention relates to a new process for concentrating epothilones in culture media, a new process for the production of epothilones, a new process for separating epothilones A and B and a new strain obtained by mutagenesis for the production of epothilones, as well as aspects related thereto. New crystal forms of epothilone B are also described.
    Type: Application
    Filed: January 8, 2004
    Publication date: July 22, 2004
    Inventors: Hans Hofmann, Marion Mahnke, Klaus Memmert, Frank Petersen, Thomas Schupp, Ernst Kusters, Michael Mutz
  • Patent number: 6656711
    Abstract: The invention relates to a new process for concentrating epothilones in culture media, a new process for the production of epothilones, a new process for separating epothilones A and B and a new strain obtained by mutagenesis for the production of epothilones, as well as aspects related thereto. New crystal forms of epothilone B are also described.
    Type: Grant
    Filed: January 29, 2002
    Date of Patent: December 2, 2003
    Assignee: Novartis AG
    Inventors: Hans Hofmann, Marion Mahnke, Klaus Memmert, Frank Petersen, Thomas Schupp, Ernst Küsters, Michael Mutz
  • Publication number: 20030220379
    Abstract: The invention relates to a new process for concentrating epothilones in culture media, a new process for the production of epothilones, a new process for separating epothilones A and B and a new strain obtained by mutagenesis for the production of epothilones, as well as aspects related thereto. New crystal forms of epothilone B are also described.
    Type: Application
    Filed: June 12, 2003
    Publication date: November 27, 2003
    Inventors: Hans Hofmann, Marion Mahnke, Klaus Memmert, Frank Petersen, Thomas Schupp, Ernst Kusters, Michael Mutz
  • Publication number: 20030194787
    Abstract: The invention relates to a new process for concentrating epothilones in culture media, a new process for the production of epothilones, a new process for separating epothilones A and B and a new strain obtained by mutagenesis for the production of epothilones, as well as aspects related thereto. New crystal forms of epothilone B are also described.
    Type: Application
    Filed: January 8, 2003
    Publication date: October 16, 2003
    Inventors: Hans Hofmann, Marion Mahnke, Klaus Memmert, Frank Petersen, Thomas Schupp, Ernst Kusters, Michael Mutz
  • Publication number: 20020192778
    Abstract: Nucleic acid molecules are isolated from Sorangium cellulosum that encode polypeptides necessary for the biosynthesis of epothilone. Disclosed are methods for the production of epothilone in recombinant hosts transformed with the genes of the invention. In this manner, epothilone can be produced in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer.
    Type: Application
    Filed: November 13, 2001
    Publication date: December 19, 2002
    Inventors: Thomas Schupp, James Madison Ligon, Istvan Molnar, Ross Zirkle, Devon Dawn Cyr, Jorn Gorlach
  • Publication number: 20020165256
    Abstract: The invention relates to a new process for concentrating epothilones in culture media, a new process for the production of epothilones, a new process for separating epothilones A and B and a new strain obtained by mutagenesis for the production of epothilones, as well as aspects related thereto. New crystal forms of epothilone B are also described.
    Type: Application
    Filed: January 29, 2002
    Publication date: November 7, 2002
    Inventors: Hans Hofmann, Marion Mahnke, Klaus Memmert, Frank Petersen, Thomas Schupp, Ernst Kusters, Michael Mutz
  • Patent number: 6383787
    Abstract: Nucleic acid molecules are isolated from Sorangium cellulosum that encode polypeptides necessary for the biosynthesis of epothilone. Disclosed are methods for the production of epothilone in recombinant hosts transformed with the genes of the invention. In this manner, epothilone can be produced in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer.
    Type: Grant
    Filed: May 10, 2000
    Date of Patent: May 7, 2002
    Assignee: Novartis AG
    Inventors: Thomas Schupp, James Madison Ligon, Istvan Molnar, Ross Zirkle, Devon Dawn Cyr, Jörn Görlach
  • Patent number: 6358719
    Abstract: Nucleic acid molecules are isolated from Sorangium cellulosum that encode polypeptides necessary for the biosynthesis of epothilone. Disclosed are methods for the production of epothilone in recombinant hosts transformed with the genes of the invention. In this manner, epothilone can be produced in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer.
    Type: Grant
    Filed: May 10, 2000
    Date of Patent: March 19, 2002
    Assignee: Novartis AG
    Inventors: Thomas Schupp, James Madison Ligon, Istvan Molnar, Ross Zirkle, Devon Dawn Cyr, Jörn Görlach
  • Patent number: 6355459
    Abstract: Nucleic acid molecules are isolated from Sorangium cellulosum that encode polypeptides necessary for the biosynthesis of epothilone. Disclosed are methods for the production of epothilone in recombinant hosts transformed with the genes of the invention. In this manner, epothilone can be produced in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer.
    Type: Grant
    Filed: May 10, 2000
    Date of Patent: March 12, 2002
    Assignee: Novartis AG
    Inventors: Thomas Schupp, James Madison Ligon, Istvan Molnar, Ross Zirkle, Devon Dawn Cyr, Jörn Görlach
  • Patent number: 6355458
    Abstract: Nucleic acid molecules are isolated from Sorangium cellulosum that encode polypeptides necessary for the biosynthesis of epothilone. Disclosed are methods for the production of epothilone in recombinant hosts transformed with the genes of the invention. In this manner, epothilone can be produced in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer.
    Type: Grant
    Filed: May 10, 2000
    Date of Patent: March 12, 2002
    Assignee: Novartis AG
    Inventors: Thomas Schupp, James Madison Ligon, Istvan Molnar, Ross Zirkle, Devon Dawn Cyr, Jörn Görlach
  • Patent number: 6355457
    Abstract: Nucleic acid molecules are isolated from Sorangium cellulosum that encode polypeptides necessary for the biosynthesis of epothilone. Disclosed are methods for the production of epothilone in recombinant hosts transformed with the genes of the invention. In this manner, epothilone can be produced in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer.
    Type: Grant
    Filed: May 10, 2000
    Date of Patent: March 12, 2002
    Assignee: Novartis AG
    Inventors: Thomas Schupp, James Madison Ligon, Istvan Molnar, Ross Zirkle, Devon Dawn Cyr, Jörn Görlach
  • Patent number: 6346404
    Abstract: Nucleic acid molecules are isolated from Sorangium cellulosum that encode polypeptides necessary for the biosynthesis of epothilone. Disclosed are methods for the production of epothilone in recombinant hosts transformed with the genes of the invention. In this manner, epothilone can be produced in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer.
    Type: Grant
    Filed: May 10, 2000
    Date of Patent: February 12, 2002
    Assignee: Novartis AG
    Inventors: Thomas Schupp, James Madison Ligon, Istvan Molnar, Ross Zirkle, Devon Dawn Cyr, Jörn Görlach
  • Patent number: 6210935
    Abstract: The present invention relates especially to a DNA fragment that is obtainable from the gene cluster within the genome of Streptomyces or Actinomyces that is responsible for staurosporin biosynthesis and that contains at least one gene or a part of a gene that codes for a polypeptide that is involved directly or indirectly in the biosynthesis of staurosporin and to methods of preparing said DNA fragment. The present invention relates furthermore to recombinant DNA molecules containing one of the DNA fragments according to the invention and to the plasmids and vectors derived therefrom. Also included are host organisms transformed with the said plasmid or vector DNA.
    Type: Grant
    Filed: March 20, 1998
    Date of Patent: April 3, 2001
    Assignee: Novartis AG
    Inventors: Thomas Schupp, Nathalie Engel, Jürg Bietenhader, Christiane Toupet, Andreas Pospiech
  • Patent number: 6194181
    Abstract: The invention relates to a new process for concentrating epothilones in culture media, a new process for the production of epothilones, a new process for separating epothilones A and B and a new strain obtained by mutagenesis for the production of epothilones, as well as aspects related thereto. New crystal forms of epothilone B are also described.
    Type: Grant
    Filed: February 12, 1999
    Date of Patent: February 27, 2001
    Assignee: Novartis AG
    Inventors: Hans Hofmann, Marion Mahnke, Klaus Memmert, Frank Petersen, Thomas Schupp, Ernst Küsters, Michael Mutz
  • Patent number: 6121029
    Abstract: Nucleic acid molecules are isolated from Sorangium cellulosum that encode polypeptides necessary for the biosynthesis of epothilone. Disclosed are methods for the production of epothilone in recombinant hosts transformed with the genes of the invention. In this manner, epothilone can be produced in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer.
    Type: Grant
    Filed: June 17, 1999
    Date of Patent: September 19, 2000
    Assignee: Novartis AG
    Inventors: Thomas Schupp, James Madison Ligon, Istvan Molnar, Ross Zirkle, Devon Dawn Cyr, Jorn Gorlach
  • Patent number: 5968992
    Abstract: In a process for reducing the primary amine content of a composition comprising at least one polyol, in which a composition comprising at least one polyol is admixed with at least one isocyanate which contains only secondary and/or tertiary, aliphatically bound isocyanate groups, isocyanate is added in an amount of up to 5% by weight, based on the total composition, and a polyol preparation is obtained.
    Type: Grant
    Filed: August 19, 1998
    Date of Patent: October 19, 1999
    Assignee: BASF Aktiengesellschaft
    Inventors: Bernhard Naber, Michael Gassan, Thomas Schupp, Sarbananda Chakrabarti
  • Patent number: 5716849
    Abstract: The present invention is directed to the production of a polyketide antibiotic such as soraphen in a host via recombinant expression of the polypeptides needed to biologically synthesize the polyketide antibiotic. Polyketide synthase (PKS) genes encoding polypeptides necessary to synthesize soraphen are provided, along with methods for identifying and isolating the PKS genes needed to recombinantly biosynthesize any desired polyketide antibiotic. The cloned PKS genes may be transformed and expressed in a desired host organisms to produce soraphen for a variety of purposes, including protecting the host from a pathogen, developing the host as a biocontrol agent, and producing large, uniform amounts of soraphen.
    Type: Grant
    Filed: December 14, 1996
    Date of Patent: February 10, 1998
    Assignee: Novartis Finance Corporation
    Inventors: James M. Ligon, Thomas Schupp, James J. Beck, Dwight S. Hill, Snezana Neff, John A. Ryals
  • Patent number: 5698425
    Abstract: The present invention is directed to the production of an antipathogenic substance (APS) in a host via recombinant expression of the polypeptides needed to biologically synthesize the APS. Genes encoding polypeptides necessary to produce particular antipathogenic substances are provided, along with methods for identifying and isolating genes needed to recombinantly biosynthesize any desired APS. The cloned genes may be transformed and expressed in a desired host organisms to produce the APS according to the invention for a variety of purposes, including protecting the host from a pathogen, developing the host as a biocontrol agent, and producing large, uniform amounts of the APS.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: December 16, 1997
    Assignee: Novartis Finance Corporation
    Inventors: James M. Ligon, Thomas Schupp, James Joseph Beck, Dwight Steven Hill, John Andrew Ryals, Stephen Ting Lam, Philip E. Hammer, Scott Joseph Uknes
  • Patent number: 5693774
    Abstract: The present invention relates to a DNA molecule isolated from the genome of Sorangium cellulosum that encodes a polypeptide required for soraphen biosynthesis and to methods for the preparation of said DNA fragment. The present invention further relates to plasmids, vectors, and host cells that comprise the DNA molecule of the invention.
    Type: Grant
    Filed: February 24, 1995
    Date of Patent: December 2, 1997
    Assignee: Novartis Finance Corporation
    Inventors: Thomas Schupp, Snezana Neff, James M. Ligon